Description

NSE notifies the listing of Sudeep Pharma Limited equity shares with effect from November 28, 2025, following IPO at issue price of Rs. 593 per share.

Summary

National Stock Exchange of India Limited has approved the listing of equity shares of Sudeep Pharma Limited on the Capital Market segment with effect from November 28, 2025. The company’s IPO consists of 112,948,625 equity shares of Re. 1/- face value issued at Rs. 593 per share. The stock will trade under symbol SUDEEPPHRM with ISIN INE0QPI01025 and market lot size of 1 share. The security will participate in the pre-open session for IPO category scrips as per SEBI regulations.

Key Points

  • Symbol: SUDEEPPHRM
  • Total Issue Size: 112,948,625 equity shares
  • Face Value: Re. 1/- per share
  • Issue Price: Rs. 593/- per share
  • ISIN: INE0QPI01025
  • Market Lot: 1 share
  • Series: EQ (Equity)
  • Pre-open Session: Applicable for IPO category
  • Lock-in: Multiple tranches with varying lock-in periods (details in shareholding pattern)
  • Registrar: MUFG Intime India Private Limited (formerly Link Intime India Private Limited)

Regulatory Changes

No regulatory changes. This is a standard listing notification under Regulation 3.1.1 and 2.5.5 of NSE (Capital Market) Trading Regulations Part A.

Compliance Requirements

  • Members must use designated security code SUDEEPPHRM for trading
  • Trading must be conducted in specified market lot size of 1 share
  • Security will participate in pre-open session as per SEBI circular CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012
  • Lock-in requirements apply to specific shareholding tranches as per Annexure I

Important Dates

  • Circular Date: November 27, 2025
  • Listing Effective Date: November 28, 2025
  • Lock-in Expiry Dates: Various dates ranging from December 25, 2025 to November 26, 2028 for different shareholding tranches
  • Financial Year: April 2025 - March 2026

Impact Assessment

Market Impact: Medium - Introduces a new pharmaceutical sector stock to NSE with substantial issue size valued at approximately Rs. 6,698 crores (112.9 million shares × Rs. 593). The high issue price indicates premium valuation, which may attract investor interest in the pharma sector.

Operational Impact: Low - Standard listing process with routine pre-open session participation. No special trading restrictions beyond normal lock-in requirements for promoter and anchor investor holdings.

Company Details:

  • Registered Office: 129/1/A, GIDC Estate, Nandesari, Vadodara - 391340, Gujarat
  • Corporate Office: 601-602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara - 391101, Gujarat
  • Company Secretary: Ms. Dimple Ashwinbhai Mehta
  • Contact: +91 265 284 0656
  • Email: cs.sudeep@sudeepgroup.com
  • Website: https://www.sudeeppharma.com

Impact Justification

Standard IPO listing notification for a pharmaceutical company. Medium impact as it introduces a new tradable security with significant issue size of 112.9 million shares at Rs. 593, but follows routine listing procedures.